BTIG Research Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price objective lowered by investment analysts at BTIG Research from $140.00 to $131.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s price target would indicate a potential upside of 28.62% from the company’s current price.

A number of other brokerages have also recently issued reports on ABT. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Oppenheimer decreased their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Daiwa Securities Group cut their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $135.68.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $101.85 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock has a 50-day simple moving average of $110.42 and a two-hundred day simple moving average of $121.79. The firm has a market capitalization of $177.39 billion, a PE ratio of 27.38, a P/E/G ratio of 1.65 and a beta of 0.74. Abbott Laboratories has a 52-week low of $101.82 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Activity

In other news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Abbott Laboratories

Several large investors have recently bought and sold shares of ABT. Brighton Jones LLC grew its position in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. United Bank boosted its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Abbott Laboratories by 37.4% during the 2nd quarter. Loomis Sayles & Co. L P now owns 47,552 shares of the healthcare product maker’s stock valued at $6,468,000 after purchasing an additional 12,939 shares during the last quarter. Finally, Edgestream Partners L.P. bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $404,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.